| Description |
1 online resource (xviii, 176 pages) : illustrations |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Woodhead Publishing series in biomaterials |
|
Woodhead Publishing series in biomaterials.
|
| Contents |
Front Cover -- Immunomodulatory Effects of Nanomaterials -- Copyright Page -- Contents -- List of contributors -- About the editor -- Preface -- Acknowledgments -- Introduction -- 1 Nanomaterials: classification, composition, and recent advances in synthesis -- 1.1 Introduction to nanotechnology -- 1.2 Terminology of nanotechnology -- 1.3 Unique properties of nanomaterials -- 1.4 Classification of nanomaterials -- 1.4.1 Polymeric nanoparticles -- 1.4.2 Nanoemulsions -- 1.4.3 Inorganic nanoparticles -- 1.4.4 Carbonaceous nanomaterials -- 1.5 Nanomaterial synthesis -- 1.6 Characterization of nanomaterials -- 1.6.1 Stability and surface chemistry -- 1.6.2 Particle size measurement and polydispersity -- 1.6.3 Electron microscopy and imaging -- 1.6.4 Ultraviolet-visible spectroscopy -- 1.7 Concluding remarks and future avenue -- References -- 2 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19* -- 2.1 Coronavirus disease-2019 -- 2.2 Morphological structure and genome -- 2.3 Clinical presentation, radiological features, and laboratory investigations -- 2.4 Therapeutic attempts -- 2.5 Antiviral therapy -- 2.6 Lopinavir/ritonavir and Arbidol -- 2.7 Immune therapy -- 2.7.1 Convalescent plasma therapy -- 2.8 Tocilizumab -- 2.9 Bamlanivimab (LY3819253 or LY-CoV555) and Etesevimab (LY3832479 or LY-CoV016) -- 2.10 Casirivimab (previously REGN10933) and imdevimab (previously REGN10987) -- 2.11 JAK inhibitors -- 2.12 Baricitinib -- 2.13 Ruxolitinib -- 2.14 Jakotinib -- 2.15 Vaccines -- 2.16 Nanoengineered therapeutics and vaccines in development for management of COVID-19 -- 2.16.1 Nanoengineered therapeutics -- 2.16.2 Nanoengineered vaccines -- 2.17 Current status and perspectives -- Acknowledgment -- References -- 3 Nanomaterials and immune system* -- 3.1 Introduction -- 3.2 The immune system. |
|
3.2.1 Structure of the immune system -- 3.2.2 Proinflammatory cytokines -- 3.3 Nanomaterials -- 3.4 Cytokines as biomarkers of immunomodulatory properties of nanomaterials -- 3.4.1 Proinflammatory cytokines as biomarkers of nanoparticle immunotoxicity -- 3.4.2 Route of administration -- 3.4.2.1 Intravenous route -- 3.4.2.2 Subcutaneous and dermal routes -- 3.4.2.3 Nasal and oral routes -- 3.4.2.4 Intraperitoneal -- 3.4.3 Endocytic pathways -- 3.4.4 The role of the nanocarriers: physicochemical characteristics -- 3.4.4.1 Size -- 3.4.4.2 Shape and hydrophobicity -- 3.4.4.3 Composition and surface modifications -- 3.4.5 The contribution of the payloads -- 3.5 Mechanisms of nanoparticle immunotoxicity -- 3.6 Relationship between cytokines and adverse reactions -- 3.7 Evaluation of nanoparticle immunotoxicity -- 3.7.1 Multiplexing principles and complications -- 3.7.1.1 Principles -- 3.7.1.2 Complications -- 3.8 Controlling the immunotoxicity of nanomaterials -- 3.8.1 Nanoparticle-related factors -- 3.8.2 Drug-related factors -- 3.9 Conclusions -- References -- 4 Methods for evaluation of the immunomodulatory effects of nanoparticles* -- 4.1 Introduction -- 4.2 Multiplexing technique for evaluation of particulate materials -- 4.3 Preassessment step: optional -- 4.4 Data mining and analysis -- References -- 5 Recommendations and use of multiplex biomarker assays -- 5.1 Introduction -- 5.1.1 Evaluation of multiplex assays -- 5.1.1.1 Selecting the right size of multiplex assay -- 5.1.1.2 Effects of sample matrix -- 5.1.1.3 Reproducibility -- 5.1.1.4 Lot-to-lot variability -- 5.1.2 Unique challenges with multiplexed assays -- 5.1.2.1 Finding the best sample dilution scheme -- 5.1.2.2 Cross-reactivity in multiplexed assays -- 5.1.2.3 Challenges of crosstalk -- 5.1.2.4 Fit for purpose validation of multiplex assays -- 5.1.2.5 Assay sensitivity. |
|
5.2 Conclusions -- References -- 6 Precautions during evaluation of immunotoxicity of particulate materials* -- References -- 7 Data analysis and interpretation* -- 7.1 Discussion -- 7.2 Method -- References -- Index -- Back Cover. |
| Bibliography |
Includes bibliographical references and index. |
| Subject |
Biomedical materials.
|
|
Nanostructured materials -- Toxicology.
|
|
Nanostructured materials -- Physiological effect.
|
|
Biomatériaux.
|
|
Nanomatériaux -- Toxicologie.
|
|
Nanomatériaux -- Effets physiologiques.
|
|
Biomedical materials
|
| Added Author |
Elsabahy, Mahmoud, editor.
|
| Other Form: |
ebook version : 9780323908245 |
|
Original 0323906044 9780323906043 (OCoLC)1284982219 |
| ISBN |
9780323908245 (electronic bk.) |
|
0323908241 (electronic bk.) |
|
9780323906043 |
|
0323906044 |
| Standard No. |
AU@ 000072198272 |
|
